Discover our complete suite of visual function test systems
Preclinical
Celeris, our flagship preclinical system, revolutionizes rodent testing with dual function stimulator-electrodes. We also offer electroretinography (ERG) solutions for other small to large animals.
Clinical
We offer four broad categories of visual function testsāvisual electrophysiology, visual psychophysical, objective acuity, and pupillometry, providing a complete picture of a personās visual function.
Trial Services
Our trial services include study setup assistance, training, and data review. These trial services enable sites to gather consistent, quality data across multiple locations worldwide.
Supporting researchers and clinicians worldwide for more than forty years
Three reasons to partner with the premier manufacturer of visual electrophysiology systems
Expertise
We design all our hardware and software in-house to our and our customersā exact specifications.
Technology
Our patented and trademarked platforms span the range from preclinical to clinical use, providing researchers and clinicians with products that have the broadest use and capability in the market.
Network
Our longstanding relationships within the electrophysiology community allow us to cross the bridge from academic labs into patient clinics, enabling easier collaboration between institutions.
Stay up to date with our latest news
-
The FST: an Effective Endpoint in Early-phase Clinical Trials of Retinal Gene Therapies
New approaches to retinal therapies such as gene therapies, optogenetics, and regenerative medicine could significantly improve the quality of life of patients with low or no vision. Endpoints play an important role in the translational…
-
Visual Electrophysiology Tests for Glaucoma Continue to Improve
In 2024, the International Society for Clinical Electrophysiology of Vision (ISCEV) updated the pattern electroretinography (PERG) test standard, which can be used to test for glaucoma. Meanwhile, the results of a study evaluating a proposed modified…
-
MLMT and FST: Effective Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Featured image: Atsena Therapeutics co-founders Shannon Boye and Sanford Boye, and a non-human primate retina stained for adeno-associated virus-vectored protein is displayed on the screen. Courtesy of Atsena Therapeutics. Gene therapy development has accelerated in…
Meet us at our upcoming events
-
20Feb
-
05Mar
-
15Mar